Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jesús‐María Hernández‐Sánchez"'
Autor:
Miguel Quijada‐Álamo, Claudia Pérez‐Carretero, María Hernández‐Sánchez, Ana‐Eugenia Rodríguez‐Vicente, Ana‐Belén Herrero, Jesús‐María Hernández‐Sánchez, Marta Martín‐Izquierdo, Sandra Santos‐Mínguez, Mónica del Rey, Teresa González, Araceli Rubio‐Martínez, Alfonso García de Coca, Julio Dávila‐Valls, José‐Ángel Hernández‐Rivas, Helen Parker, Jonathan C. Strefford, Rocío Benito, José‐Luis Ordóñez, Jesús‐María Hernández‐Rivas
Publikováno v:
Clinical and Translational Medicine, Vol 11, Iss 2, Pp n/a-n/a (2021)
Abstract Background Several genetic alterations have been identified as driver events in chronic lymphocytic leukemia (CLL) pathogenesis and oncogenic evolution. Concurrent driver alterations usually coexist within the same tumoral clone, but how the
Externí odkaz:
https://doaj.org/article/ee07f326975144ad8bd15cff85606abf
Autor:
Miguel Quijada-Álamo, María Hernández-Sánchez, Cristina Robledo, Jesús-María Hernández-Sánchez, Rocío Benito, Adrián Montaño, Ana E. Rodríguez-Vicente, Dalia Quwaider, Ana-África Martín, María García-Álvarez, María Jesús Vidal-Manceñido, Gonzalo Ferrer-Garrido, María-Pilar Delgado-Beltrán, Josefina Galende, Juan-Nicolás Rodríguez, Guillermo Martín-Núñez, José-María Alonso, Alfonso García de Coca, José A. Queizán, Magdalena Sierra, Carlos Aguilar, Alexander Kohlmann, José-Ángel Hernández, Marcos González, Jesús-María Hernández-Rivas
Publikováno v:
Journal of Hematology & Oncology, Vol 10, Iss 1, Pp 1-11 (2017)
Abstract Background Chronic lymphocytic leukemia (CLL) is a highly genetically heterogeneous disease. Although CLL has been traditionally considered as a mature B cell leukemia, few independent studies have shown that the genetic alterations may appe
Externí odkaz:
https://doaj.org/article/4acf3a07c16a4b30b54b74c2ed17f62b
Autor:
Mónica del Rey González, Sohini Chakraborty, Jesús María Hernández-Sánchez, María Diez Campelo, Christopher Y. Park, Jesús María Hernández Rivas
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Treatment with the hypomethylating agent 5-azacytidine (AZA) increases survival in high-risk (HR) myelodysplastic syndrome (MDS) patients, but predicting patient response and overall survival remains challenging. To address these issues, we analyzed
Externí odkaz:
https://doaj.org/article/c7fb6c7685b74917942b55da558c1fcc
Autor:
Juan Carlos Caballero, Julio Dávila, María López-Pavía, Esperanza Such, Teresa Bernal, Fernando Ramos, Marisa Calabuig, Jesús María Hernández Sánchez, Helena Pomares, Mercedes Sánchez Barba, María Abáigar, Bernardo González, Brayan Merchán, Reyes Sancho-Tello, Marta Callejas, Carolina Muñoz-Novas, Carlos Cerveró, Guillermo Sanz, Jesús María Hernández Rivas, María Díez Campelo;
Publikováno v:
Therapeutic Advances in Hematology, Vol 15 (2024)
Background: Erythropoiesis stimulating agents (ESAs) are the first-line therapy in patients with lower-risk myelodysplastic syndromes (LR-MDS). Some predictive factors for ESAs response have been identified. Type and number of somatic mutations have
Externí odkaz:
https://doaj.org/article/aae5bf162b0d4831a1ded6c9dd145238
Autor:
Jakob Woerner, Yidi Huang, Stephan Hutter, Carmelo Gurnari, Jesús María Hernández Sánchez, Janet Wang, Yimin Huang, Daniel Schnabel, Michael Aaby, Wanying Xu, Vedant Thorat, Dongxu Jiang, Babal K. Jha, Mehmet Koyuturk, Jaroslaw P. Maciejewski, Torsten Haferlach, Thomas LaFramboise
Publikováno v:
Nature Communications. 13
Although recent work has described the microbiome in solid tumors, microbial content in hematological malignancies is not well-characterized. Here we analyze existing deep DNA sequence data from the blood and bone marrow of 1870 patients with myeloid
Autor:
Jesús María Hernández-Rivas, Diego Alonso López, Eva Lumbreras, María Abáigar, Beatriz Arrizabalaga, Ana A. Martín, Teresa González, María Díez-Campelo, Jesús María Hernández Sánchez, Sara Erquiaga, Mónica del Rey, Raquel de Paz, Ana Eugenia Rodríguez Vicente
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
The iron chelator deferasirox is widely used in patients with iron overload. Patients with low-grade myelodysplastic syndromes (MDS) get transfusion dependency and need to be treated with deferasirox to avoid iron overload. Moreover, in some patients
Autor:
Teresa Bernal, Carme Pedro, Cristina Robledo, Eva Lumbreras, María Abáigar, Jesús María Hernández Rivas, Mercedes Sánchez Barba, Kamila Janusz, Sandra Santos Mínguez, Cristina Miguel García, Andrés Insunza, Juan Carlos Caballero, Marta Martín Izquierdo, Raquel de Paz, Rosa Collado, Maria Diez Campelo, Félix López Cadenas, Joaquín Sánchez García, Javier Sánchez del Real, Blanca Xicoy, Ana María Simón Muñoz, Eduardo Salido, Fernando Ramos, Jesús María Hernández Sánchez
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
Annals of Hematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
ANNALS OF HEMATOLOGY
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
instname
Annals of Hematology
r-IGTP. Repositorio Institucional de Producción Científica del Instituto de Investigación Germans Trias i Pujol
ANNALS OF HEMATOLOGY
r-FIHGUV. Repositorio Institucional de Producción Científica de la Fundación de Investigación del Hospital General de Valencia
SF3B1 is a highly mutated gene in myelodysplastic syndrome (MDS) patients, related to a specific subtype and parameters of good prognosis in MDS without excess blasts. More than 40% of MDS patients carry at least two myeloid-related gene mutations bu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92f234a95c3de434c14e8e4da9ee131b
http://hdl.handle.net/10261/261229
http://hdl.handle.net/10261/261229
Autor:
Félix López Cadenas, Mercedes Sánchez Barba, Jesús María Hernández Rivas, David Valcárcel, María Consuelo del Cañizo, María Abáigar, E. Lumbreras, Andres Jerez, Jesús María Hernández Sánchez, Kamila Janusz, Esperanza Such, Guillermo Sanz, Cristina Calderón Cabrera, Juan Carlos Caballero, M. Cabrero, Ana María Hurtado, José Cervera, Carmen Chillón, Maria Diez Campelo
Publikováno v:
Digital.CSIC. Repositorio Institucional del CSIC
instname
instname
Somatic mutations in patients with myelodysplastic syndromes (MDS) undergoing allogeneic hematopoietic stem cell transplantation (HSTC) are associated with adverse outcome, but the role of chronic graft-versus-host disease (cGVHD) in this subset of p
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.